Wir sind mit live! Mehr erfahren

Bioventus

BVS

Börsenwert 908 Mio. $

13,30 USD

-0,51

3,69 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-3,69 %

5 Tage

1,76 %

1 Monat

0,76 %

3 Monate

7 %

6 Monate

27,76 %

Seit Jahresbeginn

84,47 %

1 Jahr

93,31 %

5 Jahre

-3,97 %

10 Jahre

-30,77 %

Profil: Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.

Mitarbeiter: 950

Gesundheitswesen Medizintechnik

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 64,3 %

Neutral 21,4 %

Negativ 14,3 %

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale

Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. Execution focus is on demonstrating sustained cash flows, successful new product adoption, and repeat physician usage, not just early launch revenue.

Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale

Zacks Investment Research

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Zacks Investment Research

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike

Zacks Investment Research

Is Bioventus (BVS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Bioventus (BVS) Stock Undervalued Right Now?

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript

Bioventus Q2 Earnings Call Highlights

Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.

Bioventus Q2 Earnings Call Highlights

Zacks Investment Research

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus (BVS) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.21 per share a year ago.

Bioventus (BVS) Q2 Earnings Meet Estimates

Bioventus Reports Second Quarter Financial Results

DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.

Bioventus Reports Second Quarter Financial Results

Zacks Investment Research

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth

Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth

Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026

DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026.

Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt